Richard S Levy sold $1.5M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 5,000 shares at an average of $300.94, traded Nov 1, 2024, filed Nov 5, 2024.
Score components
- +15RoleDirector
- +25Trade size$1.5M at market
- +10Share of holdings soldSold 31% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.3%, 3m -4.3%, 6m -12.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-121722, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | MOption exercise Common Stock10b5-1 | +5,000 | $7.36 | $37k | 16,012 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2,800 | $300.10 | $840k | 13,212 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1,100 | $301.22 | $331k | 12,112 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -800 | $302.25 | $242k | 11,312 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -300 | $304.29 | $91k | 11,012 | Nov 5, 2024 |
| Nov 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 10,000 | Nov 5, 2024 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 46Moderate | MDGLbuy MADRIGAL PHARMACEUTICALS, INC. | Baker Bros. Advisors LP director | $25M 68,618 shares | +36% | |
| 46Moderate | MDGLbuy MADRIGAL PHARMACEUTICALS, INC. | Baker Bros. Advisors LP director | $37M 97,065 shares | +50% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | Fred B Craves director | $5.1M 15,470 shares | -4% | |
| 26Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $83k 258 shares | -2% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $637k 1,961 shares | -22% | |
| 34Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $598k 1,834 shares | -18% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $139k 415 shares | -5% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $7.1M 20,000 shares | -91% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | James M Daly director | $5.4M 15,470 shares | -89% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.